Evidence map›Paper›PMID 31204529›Full record

Trial reportLeukemia & lymphoma2019

Hybrid dosing of the cyclin-dependent kinase (CDK) inhibitor flavopiridol in relapsed/refractory mantle cell lymphoma and diffuse large B-cell lymphoma.

Milos D Miljkovic, Mark Roschewski, Kieron Dunleavy, Wyndham H Wilson

Open access · greenAbstract readClinical Trial, Phase IClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Leukemia & lymphoma, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Milos D MiljkovicLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Mark RoschewskiLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Kieron DunleavyLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Wyndham H WilsonLymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Center for Cancer Research · USNational Cancer Institute · US

Funding

Therapeutic Strategies and Molecular Correlates in Aggressive B-cell LymphomasZIASC006741 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2025
$10.4M
Molecular Biology of LymphomaZIABC011914 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSCHEWSKI, MARK · 2019 to 2025
$5.5M
LYMPHOMA STUDIESZ01SC006741 · SC · DIVISION OF CLINICAL SCIENCES - NCI · PI WILSON, WYNDHAM H · 1996 to 2008
$893k
Phase II study of flavopiridol in mantle cell lymphoma and DLBCLZ01BC010715 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2006 to 2008
$424k
Intramural NIH HHS Z01 BC010715Intramural NIH HHS Z01 SC006741
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overCyclin-Dependent KinasesDose-Response Relationship, DrugDrug Administration ScheduleDrug Resistance, NeoplasmFlavonoidsHumansInfusions, IntravenousLymphoma, Large B-Cell, DiffuseLymphoma, Mantle-CellMiddle AgedNeoplasm Recurrence, LocalPiperidinesProtein Kinase InhibitorsalvocidibCyclin-Dependent KinasesFlavonoidsPiperidinesProtein Kinase Inhibitors

Identifiers

PMID31204529
PMCPMC6917991
OpenAlexW2953096157

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.